Abstract
Background
Hepatitis B (HBV) is a vaccine-preventable infection that may cause severe infections, particularly in patients who are being treated with immunosuppressive therapy [(i.e., inflammatory bowel disease (IBD)]. Limited data are available about IBD patients’ response rate to HBV vaccine.
Aim
To assess the efficacy of HBV vaccine in IBD patients and healthy controls.
Methods
Serological markers of HBV were assessed in IBD patients, and HBV vaccine was administered to seronegative patients. The subsequent determination of anti-HBs antibody was recorded. An adequate immune response (AIR) and an effective immune response (EIR) to HBV were defined as more than 10 and 100 mIU/ml, respectively. The single dose vaccine was administered at 0, 1 and 6 months.
Results
A total of 102 patients with IBD (39 Crohn’s disease, 63 ulcerative colitis; 54 female, 48 male) and 52 (25 female, 27 male) healthy controls were included. Mean age for patients and controls were 38 ± 12 and 31 ± 8, respectively (P < 0.001). Both AIR and EIR were significantly lower in patients than in controls (P < 0.001), but they were similar between patients with CD and UC (P = 0.302). Forty-four (43%) patients were on immunosuppressive therapy before vaccination. After vaccination, 76 and 53% of the patients had AIRs and EIRs, respectively, whereas 100 and 87% of the controls had AIRs and EIRs, respectively (P < 0.001 and P < 0.001, respectively).
Conclusions
The response rate of IBD patients receiving HBV vaccinations were significantly lower compared to controls. The response rate of those receiving immunosuppressive therapy and with active disease was much too low. Vaccination should be given during remission and at immunosuppression-free times.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Macdonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science. 2005;307:1920–1925.
Lu Y, Jacobson D, Bousvaros A, et al. İmmunizations in patients with İnflammatory bowel disease. İnflamm Bowel Dis. 2009;15:1417–1423.
Yeung JH, Goodman KJ, Fedorak RN. Inadequate knowledge of immunization guidelines: A missed opportunity for preventing infection in immunocompromised IBD patients. Inflamm Bowel Dis. 02/18/2011. (Epub ahead of print). doi:10.1002/ibd.21668.
Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still’s disease. J Rheumatol. 2003;30:1624–1625.
Bernal I, Domenech E, Garcia-Planella E, et al. Opportunistic infections in patients with inflammatory bowel disease undergoing immunosuppressive therapy. Gastroenterol Hepatol. 2003;26:19–22.
Melmed GY, Ippoliti AF, Papadakis KA, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol. 2006;101:1834–1840.
WHO Publication. Hepatitis B vaccines: WHO position paper—recommendations. Vaccine. 2009;28:589–590.
Coates T, Wilson R, Patrick G, Andre F, Watson V. Hepatitis B vaccines: Assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin Ther. 2001;23:392–403.
Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: İmmunization of adults. MMWR Recomm Rep. 2006;55:1–33.
Sands BE, Cuffari C, Katz J, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2004;10:677–692.
Chaparro M, Villagrasa JR, Rodrı′guez NA, Gisbert JP. Immune response to hepatitis B vaccination in patients with inflammatory bowel disease. Gastroenterology. 2010;S138:S197.
Vida Perez L, Gomez Camacho F, Garcia Sanchez V, et al. Adequate rate of response to hepatitis B virus vaccination in patients with inflammatory bowel disease. Med Clin (Barc). 2009;132:331–335 (Abstract only).
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
Best WR, Becktel JM, Singleton JW et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444.
Gilbert MS, James RS. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. J Adoles Health. 1995;16:12–17.
Tamer A, Karabay O, Koç Nİ. The efficiency of two doses hepatitis B vaccination in health care workers for immunoprophylaxis. Turkiye Klinikleri J Med Sci. 2006;26:24–28.
Lemon SM, Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med. 1997;336:296–304.
Public Health Agency of Canada. Canadian Immunization Guide. 7th ed. 2006. [PHAC Website]. July 18, 2007. Available at: http://www.phacaspc.gc.ca/publicat/cig-gci/p03–07-eng.php. Accessed 28 June 2011.
Conflict of interest
The authors declare that they have no conflict of interest related to the publication of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Additional information
Mustafa Erhan Altunöz and Ebubekir Şenateş contributed equally to this work.
Rights and permissions
About this article
Cite this article
Altunöz, M.E., Şenateş, E., Yeşil, A. et al. Patients with Inflammatory Bowel Disease Have a Lower Response Rate to HBV Vaccination Compared to Controls. Dig Dis Sci 57, 1039–1044 (2012). https://doi.org/10.1007/s10620-011-1980-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-011-1980-8